About me
I am a biträdande lektor (assistant professor) at Michael Uhlin's group (CLINTEC, Huddinge campus). My main research interests are i) T cell based immunotherapy and ii) gamma-delta (γδ) T cells and the involvement of their different subsets in the clinical setting of cancer and infections.
My second focus is the sustainable development of research and diagnosis (mainly immunology but not exclusively) in low- and middle- income countries (LMICs).
Research description
Publications
Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse. Luo XH, Poiret T, Liu Z, Meng Q, Nagchowdhury A, Ljungman P Front Immunol 2022 ;13():1027593
Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J, Hassan M, Magalhaes I, Mattsson J J Immunother Cancer 2023 Feb;11(2):
Linear epitope mapping of the humoral response against SARS-CoV-2 in two independent African cohorts. Vigan-Womas I, Spadoni JL, Poiret T, Taïeb F, Randrianarisaona F, Faye R, Mbow AA, Gaye A, Dia N, Loucoubar C, Ny Mioramalala DJ, Ratovoson R, Randremanana RV, Sall AA, Seydi M, Noirel J, Moreau G, Simon A, Holenya P, Meyniel JP, Zagury JF, Schoenhals M Sci Rep 2023 Jan;13(1):782
Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I, Mattsson J Cancer Res 2021 06;81(11):3022-3035
Toward the understanding of a successful virus-specific T-cell therapy: T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Poiret T Br. J. Haematol. 2019 Oct;187(2):139-140
Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer. Liu Z, Poiret T, Meng Q, Rao M, von Landenberg A, Schoutrop E, et al J Transl Med 2018 07;16(1):182
Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. Poiret T, Axelsson-Robertson R, Remberger M, Luo XH, Rao M, Nagchowdhury A, et al Front Immunol 2018 ;9():760
Mucosal-Associated Invariant T Cells Display a Poor Reconstitution and Altered Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation. Solders M, Erkers T, Gorchs L, Poiret T, Remberger M, Magalhaes I, et al Front Immunol 2017 ;8():1861
Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma. Liu Z, Rao M, Poiret T, Nava S, Meng Q, von Landenberg A, et al Oncotarget 2017 Oct;8(46):80208-80222
NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma. Liu Z, Poiret T, Persson O, Meng Q, Rane L, Bartek J, et al Cancer Immunol. Immunother. 2018 02;67(2):237-246
Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis. Zhenjiang L, Rao M, Luo X, Sandberg E, Bartek J, Schoutrop E, et al EBioMedicine 2017 Sep;23():20-24
Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Liu Z, Meng Q, Bartek J, Poiret T, Persson O, Rane L, et al Oncoimmunology 2017 ;6(2):e1252894
A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Omazic B, Ayoglu B, Löhr M, Segersvärd R, Verbeke C, Magalhaes I, et al J. Immunother. 2017 Mar;():
Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning. Li Q, Rane L, Poiret T, Zou J, Magalhaes I, Ahmed R, et al Oncotarget 2016 May;7(21):30230-40
Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Meng Q, Liu Z, Rangelova E, Poiret T, Ambati A, Rane L, et al J. Immunother. ;39(2):81-9
B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis. Rao M, Valentini D, Poiret T, Dodoo E, Parida S, Zumla A, et al Clin. Infect. Dis. 2015 Oct;61Suppl 3():S225-34
T-Cell Therapy: Options for Infectious Diseases. Parida SK, Poiret T, Zhenjiang L, Meng Q, Heyckendorf J, Lange C, et al Clin. Infect. Dis. 2015 Oct;61Suppl 3():S217-24
Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients. Ambati A, Einarsdottir S, Magalhaes I, Poiret T, Bodenstein R, LeBlanc K, et al Transpl Infect Dis 2015 Jun;17(3):371-9
Increased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. Ambati A, Poiret T, Svahn BM, Valentini D, Khademi M, Kockum I, et al J. Intern. Med. 2015 Sep;278(3):264-76
TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation. Ahmed RK, Poiret T, Ambati A, Rane L, Remberger M, Omazic B, et al J. Immunother. 2014 Oct;37(8):416-25
Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. Poiret T, Rane L, Remberger M, Omazic B, Gustafsson-Jernberg A, Vudattu NK, et al BMC Immunol. 2014 Jun;15():25
Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status. Pérez-Bercoff L, Valentini D, Gaseitsiwe S, Mahdavifar S, Schutkowski M, Poiret T, et al PLoS ONE 2014 ;9(4):e89648
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, et al Lancet Respir Med 2014 Feb;2(2):108-22